Besson M, Daali Y, Di Lio A, Dayer P, Zeilhofer HU, Desmeules J. Antihyperalgesic effect of the GABA(A) ligand clobazam in a neuropathic pain model in mice: a pharmacokinetic-pharmacodynamic study. Basic Clin Pharmacol Toxicol. 2013;112(3):192–7.
https://onlinelibrary.wiley.com/doi/10.1111/bcpt.12017

Matthey A, Daali Y, Curtin F, Poncet A, Desmeules J, Besson M. GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the α2-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteers. Eur J Pain. 2020;24(6):1094-1106.
https://onlinelibrary.wiley.com/doi/10.1002/ejp.1554

Ralvenius WT, Acuna MA, Benke D, Matthey A, Daali Y, Rudolph U, et al. The clobazam metabolite N-desmethyl clobazam is an alpha2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia. Neuropharmacology. 2016;109:366–75.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981430